Synthetic biology amps up ‘decades-old’ vaccine technology

| | April 6, 2020
merlin b fedee fd c fb fb dccb superjumbo
Credit: Kent Sievers/Omaha World-Herald/AP
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

According to STAT, the Bill and Melinda Gates Foundation and the National Institute of Health (NIH) are betting on synthetic biology to outperform nature in engineering new vaccines against the COVID-19 virus.

It’s a movement several years in the works. The idea is simple: we can already “train” the human immune system to recognize, hunt down, and attack invaders using variations of the viral enemy; chunks of virus, living viruses with kneecapped infection abilities. Scientists already largely understand how to trigger a safe immune response based on the makeup of a virus.

With synthetic biology, why can’t we amp up those responses multi-fold?

Thanks to breakneck-speed advances in genome sequencing and synthesis, it’s now relatively simple to engineer components of a virus that are critical for triggering an immune response. To synthetic biologists, this represents a critical opportunity to revamp a sluggish vaccine-engineering industry based on decades-old technology. Why conform to nature when there’s a chance to outwit its designs?

Related article:  We're using a lot of experimental coronavirus treatments. That could make it harder to figure out what works

If COVID-19 ever comes back, or another coronavirus epidemic emerges—a high chance, epidemiologists say—synthetic biology could offer us a plug-and-play universal vaccine. One that’s produced at scale, doesn’t need refrigeration, and can be easily tailored to a new outbreak and shipped to the entire world.

Read the original post

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend